Delray Medical Center Among World’s Best for TBI Study
Feb 27, 2019
Delray Beach, Fla. (January 9, 2015) – Delray Medical Center made the top 10 for highest patient enrollment numbers out of the 150 sites that participated in the global Study of Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries (SyNAPSe) trial. Over a two-year period, Delray Medical Center enrolled about a dozen patients throughout Palm Beach County
.
The SyNAPSe trial, led by Dr. Lloyd Zucker, chief of neurosurgery at Delray Medical Center, evaluated the effectiveness of treating severe traumatic brain injury (TBI) patients with the reproductive progesterone hormone. Dosing began within eight hours after injury and continued for 120 hours. Patient outcomes were assessed six months later based on the Glasgow Outcome Scale.
“We are fortunate to have an outstanding neuroscience team here at Delray Medical Center, dedicated to improving patient outcomes,” said Mark Bryan, hospital CEO. “Our goal as a Level I Trauma Center is to continue participating in clinical trials that will potentially lead to new breakthroughs in patient treatment options.”
TBI is recognized as a major cause of death and disability worldwide. The Centers for Disease Control estimates that nearly 1.7 million people experience a TBI annually. A TBI can be caused by a bump, blow or jolt to the head. The effects can range from mild to severe damage to tissues that control thinking, motor skills and/or hormone production.
“I would like to thank Delray Medical Center and the trauma team for making our participation in this study a reality,” said Dr. Zucker. “The SyNAPSe study showed us that the answer to traumatic brain injury is unfortunately not progesterone. We will continue to explore other options to improve neurologic care in patients affected by both traumatic and non-traumatic neurologic disorders.”
To view the full results of the SyNAPSe Trial, visit The New English Journal of Medicine. For more information about Delray Medical Center’s neurological services, please visit www.delraymedicalctr.com/en-us/neuroscience.
.
The SyNAPSe trial, led by Dr. Lloyd Zucker, chief of neurosurgery at Delray Medical Center, evaluated the effectiveness of treating severe traumatic brain injury (TBI) patients with the reproductive progesterone hormone. Dosing began within eight hours after injury and continued for 120 hours. Patient outcomes were assessed six months later based on the Glasgow Outcome Scale.
“We are fortunate to have an outstanding neuroscience team here at Delray Medical Center, dedicated to improving patient outcomes,” said Mark Bryan, hospital CEO. “Our goal as a Level I Trauma Center is to continue participating in clinical trials that will potentially lead to new breakthroughs in patient treatment options.”
TBI is recognized as a major cause of death and disability worldwide. The Centers for Disease Control estimates that nearly 1.7 million people experience a TBI annually. A TBI can be caused by a bump, blow or jolt to the head. The effects can range from mild to severe damage to tissues that control thinking, motor skills and/or hormone production.
“I would like to thank Delray Medical Center and the trauma team for making our participation in this study a reality,” said Dr. Zucker. “The SyNAPSe study showed us that the answer to traumatic brain injury is unfortunately not progesterone. We will continue to explore other options to improve neurologic care in patients affected by both traumatic and non-traumatic neurologic disorders.”
To view the full results of the SyNAPSe Trial, visit The New English Journal of Medicine. For more information about Delray Medical Center’s neurological services, please visit www.delraymedicalctr.com/en-us/neuroscience.
